Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8274690 | 0.95 | ESR1 (0.55) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL32665639 | 0.95 | ESR1 (0.55) | ESR1ESR2DRD2DRD3OPRK1 | |
| Bromide SCHEMBL10357246 | 0.93 | ESR1 (0.54) | ESR1ESR2DRD2DRD3OPRK1 | |
| Acetic Acid SCHEMBL20533149 | 0.91 | ESR1 (0.50) | ESR1ESR2DRD2DRD3OPRK1 | |
| Acetic Acid SCHEMBL20533151 | 0.91 | ESR1 (0.50) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL32665589 | 0.87 | DRD2 (0.55) | ESR1ESR2DRD2DRD3OPRK1 | |
| Hydrochloric Acid SCHEMBL1370024 | 0.85 | DRD2 (0.53) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL2803692 | 0.80 | ACHE (0.51) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL11705084 | 0.79 | ESR1 (0.55) | ESR1ESR2DRD2DRD3OPRK1 | |
| Hydrochloric Acid SCHEMBL2807478 | 0.79 | ACHE (0.50) | ESR1ESR2DRD2DRD3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4249071-A2 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2021-11-04 | — | — | US | disclosed |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2020-07-30 | — | — | US | disclosed |
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | ESR1 4163/4885ESR2 3831/4885DRD2 4832/4885 |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | ESR1 4163/4885ESR2 3831/4885DRD2 4832/4885 |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ESR1 4163/4885ESR2 3831/4885DRD2 4832/4885 |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ESR1 4163/4885ESR2 3831/4885DRD2 4832/4885 |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | ESR1 4163/4885ESR2 3831/4885DRD2 4832/4885 |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | ESR1 4163/4885ESR2 3831/4885DRD2 4832/4885 |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | ESR1 4163/4885ESR2 3831/4885DRD2 4832/4885 |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ESR1 4163/4885ESR2 3831/4885DRD2 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.